ALT
$3.53
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases.
Recent News
Altimmune Touts Pemvidutide Progress, Targets MASH Phase 3 Start and Q3 AUD Readout at Barclays Chat
Altimmune (NASDAQ:ALT) executives highlighted clinical progress across multiple pemvidutide programs and discussed the company’s financing priorities during a Barclays fireside chat, with management pointing to upcoming catalysts in 2026 and a planned Phase 3 start in metabolic dysfunction-associate
Altimmune Details Pemvidutide MASH Path: Breakthrough Therapy, FDA Feedback, Phase 3 Next Up
Altimmune (NASDAQ:ALT) executives highlighted recent clinical and regulatory milestones for pemvidutide and outlined plans to advance a Phase 3 program in metabolic dysfunction-associated steatohepatitis (MASH) during a presentation at the Leerink Partners Global Healthcare Conference. 2025 readout
Altimmune Details Pemvidutide Phase III MASH Plans, Breakthrough Status at Citizens Conference
Altimmune (NASDAQ:ALT) executives used a presentation at the Citizens Life Sciences Conference to outline recent clinical results and development plans for pemvidutide, the company’s lead drug candidate being developed primarily for metabolic dysfunction–associated steatohepatitis (MASH). Chief Exec
Altimmune, Inc. Q4 2025 Earnings Call Summary
Moby summary of Altimmune, Inc.'s Q4 2025 earnings call
Altimmune Q4 Earnings Call Highlights
Altimmune (NASDAQ:ALT) executives used the company’s year-end 2025 results call to outline preparations for a pivotal Phase 3 program for pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH), while also providing updates on ongoing Phase 2 studies in alcohol use disorder (AUD) and